Total Clarity Wealth Management Inc. Invests $878,000 in Pfizer Inc. $PFE

Total Clarity Wealth Management Inc. bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 34,461 shares of the biopharmaceutical company’s stock, valued at approximately $878,000.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Peak Asset Management LLC boosted its holdings in shares of Pfizer by 1.4% in the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after buying an additional 402 shares during the period. Community Bank & Trust Waco Texas lifted its position in shares of Pfizer by 0.6% in the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after acquiring an additional 412 shares in the last quarter. Able Wealth Management LLC boosted its stake in Pfizer by 2.0% in the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock worth $512,000 after purchasing an additional 413 shares during the period. CVA Family Office LLC raised its stake in Pfizer by 3.3% during the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after purchasing an additional 413 shares during the period. Finally, Boltwood Capital Management lifted its holdings in shares of Pfizer by 0.7% in the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock valued at $1,485,000 after purchasing an additional 420 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $27.70.

Pfizer Stock Performance

Shares of PFE opened at $27.11 on Thursday. The firm has a market cap of $154.11 billion, a price-to-earnings ratio of 19.93 and a beta of 0.47. The company’s fifty day moving average is $26.04 and its 200-day moving average is $25.37. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. Pfizer’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA gives full approval to Pfizer’s BRAFTOVI combination for first‑line metastatic colorectal cancer — a clear commercial positive for oncology revenue and uptake. Read More.
• Positive Sentiment: Pfizer secures China commercialization partner (Sciwind) for a next‑generation weight‑loss GLP‑1 candidate, expanding market access in a high‑growth obesity/diabetes segment and unlocking up to ~$495M in deal value. Read More.
• Positive Sentiment: Dividend narratives strengthen investor interest — coverage pieces highlight Pfizer’s high yield and management’s commitment to the payout, supporting income‑oriented demand. Read More.
• Neutral Sentiment: Pfizer updated clinical activity in China (pneumococcal vaccine Phase 1) — constructive for long‑term vaccine opportunity but near‑term commercial impact is unclear. Read More.
• Neutral Sentiment: Industry pieces and comparisons (Novo Nordisk, J&J, large‑cap pharma commentary) are placing Pfizer within a broader sector narrative about defensiveness and AI‑driven R&D — useful context but not company‑specific catalysts. Read More.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform/“$25” target and warned of an expected $15B–$20B structural revenue decline through 2030 — a significant bearish forecast that pressures valuation expectations. Read More.
• Negative Sentiment: Zacks moved Pfizer from “strong sell” to “hold,” improving its tone but reflecting continued analyst caution; RBC/other outlets are still negative which keeps analyst sentiment mixed. Read More.
• Negative Sentiment: Pfizer terminated an early‑stage ulcerative colitis study (Phase 1b), representing a pipeline setback and incremental downside risk to future growth prospects. Read More.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.